Latest news
Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 12:13:26 GMTPfizer (NYSE: PFE) boosts 2026 revenue view and details $6.7B cost cuts - Stock TitanStock Titan · Tue, 04 Aug 2026 11:03:24 GMTPhase III Trials Show Positive Results for Ritlecitinib in Nonsegmental Vitiligo - Medical DialoguesMedical Dialogues · Sun, 02 Aug 2026 23:30:18 GMTPfizer’s Litfulo meets Phase III goals in vitiligo, supporting regulatory filings - The Pharma LetterThe Pharma Letter · Fri, 31 Jul 2026 07:00:00 GMTPfizer cues up vitiligo filing for Litfulo after phase 3 win - pharmaphorumpharmaphorum · Thu, 30 Jul 2026 18:50:22 GMTPfizer seeks label expansion for Litfulo after double Phase III NSV win - Clinical Trials ArenaClinical Trials Arena · Thu, 30 Jul 2026 15:45:49 GMTPfizer announces phase 3 results for nonsegmental vitiligo treatment - PMLiVEPMLiVE · Thu, 30 Jul 2026 11:38:37 GMTPfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie - Fierce PharmaFierce Pharma · Thu, 30 Jul 2026 07:00:00 GMT